(Q33327891)

25 July 2017

title

Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma (English)

1 reference

malignant pleural mesothelioma

25 July 2017

main subject

1 reference

1 reference

A Purohit

1

1 reference

25 July 2017

L Moreau

2

1 reference

25 July 2017

A Dietemann

3

1 reference

25 July 2017

R Seibert

4

1 reference

25 July 2017

G Pauli

5

1 reference

25 July 2017

J M Wihlm

6

1 reference

25 July 2017

E Quoix

7

1 reference

25 July 2017

publication date

1 November 1998

1 reference

25 July 2017

1 reference

25 July 2017

volume

22

1 reference

25 July 2017

issue

2

1 reference

25 July 2017

page(s)

119-125

1 reference

Current Therapy for Mesothelioma

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Malignant pleural mesothelioma in western Glasgow 1980-6.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Continuing increase in mesothelioma mortality in Britain.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Chemosensitivity and cytokine sensitivity of malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Chemotherapy in malignant pleural mesothelioma. A review.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Alpha interferon for induction of remission in hairy-cell leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

HLA antigen expression and malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Effect of interferon-alpha 2a on malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Treatment of a patient with malignant mesothelioma with interferon-alpha 2 based on in vitro sensitivity tests.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Interferon-alpha and -gamma in combination with chemotherapeutic drugs: in vitro sensitivity studies in four human mesothelioma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

The calculation of received dose intensity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

High-dose cisplatin in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Efficacy of the anticancer agent cisplatin in the treatment of human cervical squamous carcinoma xenografted in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

Weekly high-dose cisplatin in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2898%2900072-5

7 January 2021

10.1016/S0169-5002(98)00072-5

Identifiers

DOI

1 reference

25 July 2017

1 reference